Neoadjuvant Nivolumab, Docetaxel, Cisplatin Therapy Followed by Surgery and Radiation Therapy for Resectable High Grade Salivary Gland Carcinoma

NCT05727410 · clinicaltrials.gov ↗
PHASE2
Phase
RECRUITING
Status
50
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Myung-Ju Ahn